Aripiprazole Tablet
Product Images NDC 63629-7774

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 63629-7774). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

Chemical structure of aripiprazole, showing its molecular framework with chlorinated aromatic rings and other structural features typical of this active ingredient.*

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for AUC and Cmax of aripiprazole when coadministered with various drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). The x-axis represents change relative to a reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing dehydro-aripiprazole fold change with 90% confidence intervals. It compares the area under the curve (AUC) and maximum concentration (Cmax) for Aripiprazole when taken with CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam. The x-axis displays change relative to reference without interacting drug.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

A forest plot titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs relative to a reference without interacting drug. The y-axis lists drugs metabolized by enzymes such as CYP2D6, CYP2C9, and UGT1A4, including dextromethorphan, warfarin, omeprazole, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis displays change relative to reference from 0.5 to 3.0, illustrating Aripiprazole's pharmacokinetic influence on the area under curve (AUC) and maximum concentration (Cmax) of these drugs.*

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' displaying fold changes in AUC and Cmax for special populations, including differences by CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference from 0.5 to 3.0.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the fold change in AUC and Cmax relative to reference for various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The horizontal axis represents change relative to reference values, with data points and error bars indicating confidence intervals for each comparison.*

FDA Label Image

Fig-6 (Aripiprazole Tablets 7)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over time in days from randomization, comparing Aripiprazole and placebo groups. The chart includes the number of subjects at risk for each group at various time points, with Aripiprazole represented by a solid blue line and placebo by a dashed red line.*

FDA Label Image

01 (Aripiprazole Tablets 8)

A Kaplan-Meier curve showing the proportion of subjects with relapse over 182 days from randomization for Aripiprazole and placebo groups. The graph includes numbers of subjects at risk at multiple time points for each group, demonstrating relapse rates over time.*

FDA Label Image

0102 (Aripiprazole Tablets 9)

A line graph comparing proportion with relapse over days from randomization between Aripiprazole and Placebo groups. The x-axis represents days from randomization up to 364, and the y-axis shows the proportion with relapse from 0.0 to 1.0. A legend differentiates Aripiprazole (solid line) from Placebo (dashed line). The number of subjects at risk is shown at multiple time points for each group below the x-axis.*

FDA Label Image

Label Image (Lbl636297774)

The label is for Aripiprazole 30mg tablets packaged by Bryant Ranch Prepack, Burbank, CA. It states the product is a pink round tablet with imprint AN902;30. The label compares this product to Abilify 30mg tablets by Amneal Pharmaceuticals Pvt. Ltd. Storage instructions note keeping the tablets at 20°-25°C (68°-77°F) and out of reach of children. The NDC number shown is 63629-7774-1 with a lot number 1523487 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.